Study shows comparable efficacy of Tristel Wipes
Wed, 24th Jan 2018 07:00
RNS Number : 7135C
24 January 2018
("Tristel" or "the Company")
Study shows comparable efficacy of Tristel Wipes
Tristel's chlorine dioxide wipes are validated as a viable alternative to peracetic acid disinfectants for the high-level disinfection of flexible nasendoscopes
Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that a study conducted at the Khoo Tech Puat Hospital, Singapore, has concluded that the Tristel Wipe has comparable efficacy to a world leading peracetic acid high-level disinfectant (Rapicide; Cantel Medical, New Jersey, USA), and provides significant other advantages to a hospital.
The study has been published in the International Journal of Otorhinolaryngology and Head and Neck Surgery (Gan YJ et al. Int J. Otorhinolaryngol Head Neck Surg. 2018 Jan; 4(1):18-23). Cantel is one of the world's largest dedicated infection prevention companies quoted on the NYSE.
The study took place in the Ear, Nose and Throat clinic during 2014. One hundred patients volunteered to participate and for each endoscopic examination one nasendoscope disinfected by Rapicide and one nasendoscope disinfected by a Tristel Wipe was used to scope each nasal passage of the patient. From swabbing each nasendoscope pre and post disinfection to reveal evidence of bacterial contamination the study concludes that Rapicide and the Tristel Wipe are statistically equivalent in terms of efficacy.
In addition to being comparable with Rapicide the study identifies other significant advantages of the Tristel Wipe. These benefits are rapid turnaround of the nasendoscope (2-3 minutes for Tristel versus 20 minutes for Rapicide) which means the clinic can see more patients in a day with fewer nasendoscopes; Tristel's safety from a health standpoint, and the Tristel Wipe's portability which means that it can be easily taken to the emergency department or to the wards. This is important as even though most ENT departments are out-patient areas, frequently in-patients carry MRSA, vancomycin-resistant Enterococci (VRE), and even tuberculosis, and need to have a nasendoscopy. The Tristel Wipe can easily be taken to them to enable the examination.
The Tristel Wipes System is a unique, patented decontamination method for non-lumened endoscopes and ultrasound probes. It has been a very significant sales success for the Company globally. Worldwide sales of the Wipes System in the financial year ending June 2017 were £11.5m.
Paul Swinney, CEO, comments: "We are pleased to see the publication in a peer-reviewed journal of yet another study comparing our Wipe with a leading peracetic acid high-level disinfectant - Cantel's Rapicide product. Peracetic acid is the most widely used high-level disinfectant chemistry in Europe and probably the United States also. The results affirm the key advantages of our Wipes over alternative chemistries and disinfection methods. These advantages are the level and speed of kill and the capability of our Wipe System to be deployed anywhere within a healthcare setting without the need for power, water and space. This is the thirty first peer-reviewed and published scientific paper featuring Tristel products - a body of evidence of our products' attributes that forms one of our Company's key strengths."
I got a little worried with the SP drift in the run up to he 'Santa Rally' when the reindeer were heading south.
There has been volatility in the SP for some time, not surprising when you consider the rise but the recent dips have hit my bottom line and I have sold down a percentage of my stock as we still seem to be in a downward trend.
Can I say that I will buy back should this drop further which seems likely with no news.
"Events at LSE:TSTL:Tristel are a reminder that complicated remuneration schemes masking inflated executive pay extend way beyond the big companies and 'fat cats' that make it into the headlines. Boards showing restraint, in my opinion, are ..."
"I'm wondering about Tristel, Richard. You named it as one of the 'popular' shares in the Share Sleuth portfolio. And by popular I sensed you meant it may be overpriced.Hmmm. Kind of. There's lots of speculation in the price. At 280p it values the ..."
Re previous message, I should add that the vesting target prices are
fair an correct, IMO. However, the total value would amount to above
£4m, which is to all intents and purposes a very large bite out of
Almost a million shares give-away, equating in rough figures to
say £3m value, which is not far below last year's post-tax profits.
Personally I do not like the name 'Options', when the excercise
price is 1p, which might as well be zero. In my view Options
should be at an exercise price above current share price or
recent average share price.
Can anyone explain that the EDA delay will not have a bearing on expected N America revenues after this unexpected five month delay?
"Whilst we are disappointed that the EPA's change of approach will require us to restart the submission timetable and incur a five-month delay to the timetable that we originally anticipated, our expectation for first revenues from North America in financial year 2018-19 remains unchanged." Paul Swinney, CEO,
The share price had run away with itself and put itself on a seriously punchy PE. And all in anticipation of good news rather than solid news. I sold out at 3.05 and will wait for a re-entry as it's my opinion this is still a pretty punchy valuation for any results that are anything other than stellar.
Well after many trading days up pretty big swings. It seems that pressure is generally downward and has made a mess of my SIPP and ISA. Its odd so close to results? I can't find any news and its on V low volume, so must be PI's running for them there hills and cash.
Do we ever know what the real trade volume is? It often seems that 2-4 weeks after an institutional player has bought/sold a large chunk, the information slips out. Or maybe the market maker gets wind of a major interest or plans to sell and anticipates the action.
Perhaps a large seller waiting in the wings, with market makers
aware of that not taking shares on board. Thus every little sell
takes the share price down further. I can see no other reason.
The shares were perhaps rather over-valued and indeed may
still be over-valued?
I think this is case of where the real value, x earnings of the company lies and a lot of value has been placed on the america case. I think what happens then is many PIs like me are almost left with little option but to sell, when the SP drops this far, this quickly, to protect pension and wait for some sense of what the floor might be. The results will be interesting.
However you are right volume is tiny, so why this is having what would appear to be a disproportionate impact on the SP?
I agree. We have seen almost unopposed upwards movement in recent months. The usual pattern is price drift before results.
Apart from a sell order from a director 6 weeks ago, there has been no news.
This has the smell of market makers looking for volume.
For once it does seem that I hit the sell button at the right time. The drop smells of some people being in the know about current progress (or more likely - lack thereof) that justifies a pull back from the recent share price high. And of course, the news gets to just a few before it does the rest of the market. We wont be in the know until an official RNS but some obviously know before we do.
Been trying to buy a grands worth of these for about an hour. Keep getting a your order can't be met, place order. Maybe one or two of those post about the expensive nature of the SP, could sell as few shares to ease the situation.
Yes, looking expensive now. Very. I sold out last week at a near 200% profit on the basis that the share price has stormed ahead without any real news. Its all on the possibility of the US. If that comes through (of which there is no guarantee) then I might miss a reactive spike up, but my personal opinion is that there is going to have to be a massive spend in order to penetrate the US market. I think the shares are looking pricey and Ive banked my profit. Will get back in if there is a punchy fall but right now Im grateful for a good run and a handsome profit. Split the proceeds and put into Melrose, ITV and Avacta instead as am hoping that there is longterm potential in a well run business (Melrose) an overdone share fall (ITV), and possibility of a repeat of Tristel (Avacta)! Knowing my luck I should have just sat tight as Tristel may rocket!
I agree with the US. Update on that will be interesting. Is there also something to do with availability of shares. A number of times I have tried to purchase shares for the Buy order to default to a Place Order ( could be iii systems?). Small volume and the spread?
I think the kicker here is the USA , success in the US market will make what has gone before chicken feed
I have been invested here for many years , I like the management, one of the few companies to get in touch with private investors and issue invites to visit . I never did because it's a long way from here . I sold a few back in the £1.70 's which was obviously not too clever with hindsight , I shall continue to hold the balance because if the US is a success I can see a takeover is possible.
Anyway nothing is certain so you pays your money and take your chances .
Superb share price performance, obviously on the back of very positive trading and going into US market, but surely now looking very expensive on moat criteria. Results not due until 19.10.17
" PS to SI "after successful American venture/s! " +1 esp with MRSA becoming a major problem with resistance to Vancomycin"
Thanks for the update. MRSA strains developing Vancomycin resistance isn't a good news to the medical world. If tristel products are useful in preventing spread of MRSA, C.Diff and similar superbugs (there by reducing the morbidity rates), this company has a very bright future. It would be interesting to find any data about incidence of MRSA, before and after tristel products were introduced in various U.K. Hospitals.
Retired endoscopist/surgeon here. I did think there were big advantages to chlorine dioxide. Some years ago I tipped off my head of dept <at about 30p> and they trialled it. If there are multiple channels in a 'scope, as for through mouth and up other end, because you need to blow in air and also pass instruments, then there are better alternatives. If you are looking to wipe down an instrument (think back of nose) or clean other simple surfaces then it is very cost effective. To be honest my examinations of the cervix has been more social than professional but from the website:
it looks like this is a wipe down product and so a natural fit, so as to speak. The key is portability, no need for large tubs/vats pumps etc, just a packet of damp tissues.
Is this a charitable donation? My share of this company is miniscule but $750,000 is only about ten times the return I have already had from my few shares in TSTL and I would be happy that the company make a donation on my behalf. But professionally I would think this was sensible support and as a PI I am totally supportive. Further there must be thousands of potential EVA systems, not all nor even many of which need sterilization but for a simple example video dermatology has revolutionised the management of "moles" in many countries like UK, NZ and Auz.
PS to SI "after successful American venture/s! " +1 esp with MRSA becoming a major problem with resistance to Vancomycin.
Not quite sure why you think they are being so charitable. The amount TSTL are putting up is a relatively small part of a much larger fund-raising by Mobile ODT. The stated objective is to pursue a partnership with Mobile ODT under which their kit is sold in a package with the disinfectant products which are essential for it. On the face of it this is a deal which could be quite reasonably called strategic. But I am not an endoscopy expert - I think we would all be happy to hear if you have better information.
Whilst laudable from an ethical viewpoint, I would suggest that Tristel's $750,000 investment in Mobile ODT borders on a charitable donation, looking at the markets Mobile ODT appears to be aiming at. However, I also notice a VC is investing so perhaps there is some investment sense there. Also a bit concerned about Tristel becoming involved with an early stage investment - I did not realise investing was part of the business plan. This may also have tax implications for some shareholders who benefit from the inheritance tax exemption for holdings in AIM companies. I would regard this as a radical and concerning departure from Tristel's normal business.
Yesterday, I visited tristel's display stall at Geneva palexpo. It was good. Out of nearly 100 display stalls showing pharma and medical equipments, many competing with each other, tristel stall was unique being only one of its kind. Hope the company does well.
Well, we shall know by tomorrow if there's any negative news on the way.
Quite a few well performing smallcaps in my portfolio fell today and I think a bout of profit taking is overdue. Perhaps this will continue for a while as prices are quite high. Not aware of any problems at Tristel.
Important message from the Financial Conduct Authority:
Posting inside information that is not public knowledge, or information that is false or misleading, may constitute market abuse.
This could lead to an unlimited fine and up to seven years in prison.
If you have any information, concerns or queries about market abuse, click here.
The content of the messages posted represents the opinions of the author, and does not represent the opinions of Interactive Investor Trading Limited or its affiliates and has not been approved or issued by Interactive Investor Trading Limited.
You should be aware that the other participants of the above discussion group are strangers to you and may make statements which may be misleading, deceptive or wrong.
Please remember that the value of investments or income from them may go down as well as up and that the past performance of an investment is not a guide to its performance in the future.
The discussion boards on this site are intended to be an information sharing forum and is not intended to address your particular requirements.
Whilst information provided on them can help with your investment research you need to consider carefully whether you should make (or refraining from making) investment or other decisions based on what you see without doing further research on investments you are interested in.
Participating in this forum cannot be a substitute for obtaining advice from an appropriate expert independent adviser who takes into account your circumstances and specific investment needs in selected investments that are appropriate for you.